clinical trial · NCT03941236
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Zealand Pharma·phase3·active not recruiting·n = 42
Congenital Hyperinsulinismdasiglucagon
brief summary
This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 or ZP4207-17109 (defined as lead-in trials). The primary objective is to evaluate the long-term safety of dasiglucagon administered as a subcutaneous (SC) infusion in children with CHI.
started
May 2, 2019
primary completion
Jan 28, 2025
completion
Dec 31, 2026
last updated
Jan 20, 2026
official title
An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol